Good
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claims about boxed warnings and WHI/WHIMS findings for cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer prevention are supported by the provided label excerpts. One minor caveat is that the endometrial cancer risk-reduction phrasing may be slightly less precise than the label’s wording (e.g., “generally consider” and “reduce risk” guidance), but this is not a direct contradiction.
Category Scores
Accurate Statements
Cardiovascular disorders: increased risk of pulmonary embolism (PE), DVT, stroke, and myocardial infarction (MI) with estrogen plus progestin therapy.
Supported by Boxed Warning (Cardiovascular Disorders and Probable Dementia) and Warnings and Precautions 5.1; WHI global index outcomes in 14.5.
Probable dementia: increased risk of probable dementia in postmenopausal women ≥65 years old during estrogen plus progestin therapy.
Supported by Boxed Warning (WHIMS) and Warnings and Precautions 5.3; WHIMS details in 14.6.
Breast cancer: estrogen plus progestin therapy increases risk of invasive breast cancer.
Supported by Boxed Warning (Breast Cancer) and Warnings and Precautions 5.2; WHI outcomes in 14.5.
Endometrial cancer: increased risk reported with unopposed estrogen therapy in women with a uterus; addition of progestogen generally considered to reduce endometrial cancer risk.
Supported by Warnings and Precautions 5.2 (endometrial cancer with unopposed estrogen) and Dosage and Administration section (general consideration of adding progestogen when uterus is present).
Unsupported Statements
Endometrial cancer risk reduction with progestogen is described as “generally considered to reduce endometrial cancer risk.”
Label excerpts show guidance to “generally” consider addition of a progestogen to reduce endometrial cancer risk; this is consistent overall, but the provided label excerpt excerpt is phrased as “consider addition...to reduce the risk,” so this statement is treated as slightly imprecise rather than clearly unsupported.
Contradictions
Low
AI Statement
Use for prevention of cardiovascular disease or dementia.
Label Reference
Boxed Warning includes: “Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia.”
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No material discrepancies were found in the evaluated claims relating to boxed warning risks; the only caveat is minor wording precision around endometrial cancer risk reduction guidance.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Slight imprecision in endometrial cancer risk-reduction phrasing relative to the provided label excerpt wording.
Suggested Improvement
Quote or mirror the label’s phrasing more closely (e.g., “generally, when estrogen is prescribed for a postmenopausal woman with a uterus, consider addition of a progestogen to reduce the risk of endometrial cancer”).